Array BioPharma Inc. (ARRY:NASDAQ)
Array BioPharma Inc. (ARRY:NASDAQ) has a market of $565M. This firm is working on late-stage clinical programs with modest expectations. Array’s binimetinib is currently being developed for ovarian cancer and melanomas, but combinations provide for a long-lived pipeline. An ex-US partnership is expected.
Array BioPharma’s mix win in melanoma puts it financially behind, however maybe clinically in front of, Novartis (NYSE:NVS) and Roche (OTCQX:RHHBY). Movement free survival of 14.9 months for the binimetinib and encorafenib doublet is numerically superior to that of advertised contenders from the two Swiss gatherings, yet the littler biotech will come late